Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure I: Introduction

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction.

European journal of heart failure·2024

Same author

Phenotyping patients with chronic obstructive pulmonary disease and heart failure.

ESC heart failure·2024

Same author

Donor age and ischemic time in heart transplantation - implications for organ preservation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2024

Same author

Association of non-cardiac comorbidities and sex with long-term Re-hospitalization for heart failure.

European journal of internal medicine·2024

Same author

Trends in heart failure mortality in Sweden between 1997 and 2022.

European journal of heart failure·2024

Same author

A novel model of cardiovascular-kidney-metabolic syndrome combining unilateral nephrectomy and high-salt-sugar-fat diet in mice.

Lab animal·2024

Search research articles

Related Experiment Video

Updated: Feb 16, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

Negotiating renal dysfunction when treating patients with heart failure.

Valentina Carubelli¹, Marco Metra¹, Lars H Lund²

¹a Division of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health , University and Civil Hospital of Brescia , Brescia , Italy.

Expert Review of Cardiovascular Therapy

|January 3, 2018

Summary

This summary is machine-generated.

Chronic kidney disease (CKD) is common in heart failure (HF), with no specific treatments for cardiorenal syndrome. This review explores heart-kidney interactions and therapeutic challenges in managing these intertwined conditions.

Keywords:

Heart failure chronic kidney disease renal dysfunction treatment

More Related Videos

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

Related Experiment Videos

Last Updated: Feb 16, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

Area of Science:

Cardiology
Nephrology
Cardiorenal Medicine

Background:

Chronic kidney disease (CKD) is a frequent comorbidity in heart failure (HF).
Cardiorenal syndrome lacks specific treatments, despite the close pathophysiological link between heart and kidney function.
CKD adversely affects HF outcomes, while cardiovascular events are leading causes of mortality in CKD patients.

Purpose of the Study:

To review the interaction between heart and kidney function.
To describe the consequences of cardiorenal syndrome.
To focus on the application of current therapeutics for cardiorenal syndrome.

Main Methods:

Literature review of cardiorenal syndrome.
Analysis of pathophysiological mechanisms.
Discussion of therapeutic management challenges.

Main Results:

Multiple mechanisms, including hemodynamic, neurohormonal, and inflammatory mediators, contribute to cardiorenal syndrome.
Managing HF drugs in CKD patients presents challenges, such as reduced diuretic response and increased risk of kidney function decline.
Balancing cardiac and renal outcomes is a critical aspect of clinical practice.

Conclusions:

The intricate relationship between heart and kidney necessitates a careful therapeutic approach.
Optimizing treatment for cardiorenal syndrome requires a nuanced understanding of both cardiac and renal physiology.
Further research is needed to develop targeted therapies for cardiorenal syndrome.